Sacituzumab Govitecan & Pembrolizumab: 40% Bladder Cancer Response – SURE-02 Trial

For patients facing muscle-invasive bladder cancer, a novel combination therapy is offering a potential path toward bladder preservation, according to findings from the phase II SURE-02 trial. Approximately 39% of individuals ineligible for standard cisplatin chemotherapy experienced a clinical complete response after treatment with sacituzumab govitecan and pembrolizumab, raising hopes for a less invasive treatment approach.

A New Option for Cisplatin-Ineligible Patients

Muscle-invasive bladder cancer (MIBC) typically requires radical cystectomy – surgical removal of the bladder – alongside chemotherapy using cisplatin. However, roughly half of those diagnosed either cannot tolerate cisplatin due to pre-existing health conditions or choose to avoid its side effects. This leaves a significant gap in treatment options. Both pembrolizumab and sacituzumab govitecan have previously demonstrated some effectiveness when used individually as neoadjuvant therapies (given before surgery), prompting researchers to investigate their combined potential within a strategy designed to spare the bladder in select cases.

The SURE-02 trial, conducted at the IRCCS San Raffaele Hospital in Milan, Italy, enrolled 49 adults with MIBC who were either ineligible for or had declined cisplatin treatment. Participants received four cycles of neoadjuvant therapy consisting of pembrolizumab (200mg intravenously) and sacituzumab govitecan (7.5mg/kg intravenously), administered every three weeks. Following this, patients either underwent radical cystectomy or, after discussion with a multidisciplinary team, a repeat transurethral resection of bladder tumor (re-TURBT) if they wished to explore bladder preservation. Those who did not proceed with cystectomy received adjuvant pembrolizumab for 13 cycles.

Understanding the Trial Findings and Limitations

The primary endpoint of the trial was clinical complete response (cCR), defined as negative imaging results combined with the absence of viable tumor cells during re-TURBT for patients pursuing bladder-sparing treatment. The results showed a cCR rate of 39% (19 out of 49 patients), with a 95% confidence interval ranging from 25% to 54%. Importantly, all patients who achieved a cCR underwent re-TURBT and all remained free of metastasis at the time of data cutoff. However, two patients experienced intravesical relapse – a recurrence of cancer within the bladder.

The study’s design, being a single-arm phase II trial, means it doesn’t include a control group for direct comparison. This limits the ability to definitively state how much more effective this combination therapy is compared to existing alternatives. The relatively small sample size (49 patients) means the findings may not be fully representative of the broader MIBC population. The median follow-up period of 14 months is also relatively short, meaning long-term outcomes and potential late recurrences remain unknown. As noted in a report from JCO, biomarker results are also being analyzed to identify factors that might predict which patients are most likely to benefit from this treatment approach.

What These Findings Mean for Patients

The 39% cCR rate is encouraging, particularly for patients who are not candidates for cisplatin-based chemotherapy. It suggests that a significant proportion of these individuals may be able to avoid radical cystectomy and preserve their bladder function. However, it’s crucial to remember that this is not a guaranteed outcome. The two cases of intravesical relapse highlight the possibility of recurrence even after achieving a complete response.

Sacituzumab govitecan is a first-in-class antibody-drug conjugate, meaning it delivers chemotherapy directly to cancer cells, potentially minimizing damage to healthy tissues. Pembrolizumab is an immunotherapy drug that helps the body’s immune system recognize and attack cancer cells. The combination aims to leverage both mechanisms to achieve a more robust anti-cancer effect. Medscape reports that this approach is showing promise, but further research is needed to confirm these initial findings.

Safety and Manageability

The treatment was generally well-tolerated, with grade 3 adverse events – serious side effects requiring intervention – observed in 16% of patients. Diarrhea was the most frequently reported severe event (8%). Importantly, no grade 4 or grade 5 treatment-related toxicities (life-threatening or fatal events) or treatment-related deaths were recorded. This suggests that the combination therapy has a manageable safety profile, even in patients who may be more vulnerable due to their ineligibility for cisplatin.

The Path Forward: Further Research and Clinical Implementation

The SURE-02 trial represents an critical step forward in the treatment of muscle-invasive bladder cancer, particularly for those who cannot receive cisplatin. However, several key questions remain. Larger, randomized controlled trials are needed to confirm these findings and compare the combination therapy to other treatment options. Researchers are also investigating biomarkers that could facilitate identify patients most likely to benefit from this approach.

The trial’s findings support a potential bladder-preserving perioperative strategy, but careful patient selection and close monitoring are essential. The role of re-TURBT in assessing response and guiding treatment decisions also warrants further investigation. OncoDaily details the trial’s methodology and findings, emphasizing the necessitate for continued research to refine this approach.

Next Steps in Evaluating the Combination

Ongoing research will focus on refining patient selection criteria, optimizing the treatment schedule, and identifying predictive biomarkers. Further trials will also aim to assess the long-term efficacy and safety of this combination therapy, as well as its impact on quality of life. Clinicians will continue to monitor emerging data and guidelines to determine the best way to incorporate this promising new treatment option into clinical practice.